{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:33:07Z","timestamp":1787502787854,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T00:00:00Z","timestamp":1736553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100008385","name":"Fondazione per la Ricerca sulla Fibrosi Cistica","doi-asserted-by":"publisher","award":["FFC#2\/2020; FFC#1\/2022"],"award-info":[{"award-number":["FFC#2\/2020; FFC#1\/2022"]}],"id":[{"id":"10.13039\/501100008385","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Glycoconj J"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s10719-024-10174-7","type":"journal-article","created":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T04:49:24Z","timestamp":1736570964000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of CFTR modulators Elexacaftor\/Tezacaftor\/Ivacaftor on lipid metabolism in human bronchial epithelial cells"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9536-5912","authenticated-orcid":false,"given":"Dorina","family":"Dobi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2741-7418","authenticated-orcid":false,"given":"Nicoletta","family":"Loberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4194-4804","authenticated-orcid":false,"given":"Laura","family":"Mauri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7409-4730","authenticated-orcid":false,"given":"Rosaria","family":"Bassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7431-9207","authenticated-orcid":false,"given":"Elena","family":"Chiricozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3099-3395","authenticated-orcid":false,"given":"Giulia","family":"Lunghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1916-2440","authenticated-orcid":false,"given":"Massimo","family":"Aureli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,11]]},"reference":[{"issue":"2","key":"10174_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1046\/j.1432-1327.1998.2570293.x","volume":"257","author":"MA Chester","year":"1998","unstructured":"Chester, M.A.: IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN). Nomenclature of glycolipids--recommendations 1997. Eur J Biochem 257(2), 293\u20138 (1998)","journal-title":"Eur J Biochem"},{"key":"10174_CR2","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1146\/annurev.biochem.75.103004.142532","volume":"77","author":"JR Riordan","year":"2008","unstructured":"Riordan, J.R.: CFTR function and prospects for therapy. Annu. Rev. Biochem. 77, 701\u2013726 (2008)","journal-title":"Annu. Rev. Biochem."},{"issue":"9678","key":"10174_CR3","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","volume":"373","author":"BP O'Sullivan","year":"2009","unstructured":"O\u2019Sullivan, B.P., Freedman, S.D.: Cystic fibrosis. Lancet 373(9678), 1891\u20131904 (2009)","journal-title":"Lancet"},{"issue":"4","key":"10174_CR4","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/0092-8674(90)90148-8","volume":"63","author":"SH Cheng","year":"1990","unstructured":"Cheng, S.H., et al.: Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63(4), 827\u2013834 (1990)","journal-title":"Cell"},{"issue":"3","key":"10174_CR5","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1091\/mbc.e14-04-0935","volume":"27","author":"G Veit","year":"2016","unstructured":"Veit, G., et al.: From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol. Biol. Cell 27(3), 424\u2013433 (2016)","journal-title":"Mol. Biol. Cell"},{"issue":"10059","key":"10174_CR6","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1016\/S0140-6736(16)00576-6","volume":"388","author":"JS Elborn","year":"2016","unstructured":"Elborn, J.S.: Cystic fibrosis. Lancet 388(10059), 2519\u20132531 (2016)","journal-title":"Lancet"},{"issue":"1","key":"10174_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nrg3849","volume":"16","author":"GR Cutting","year":"2015","unstructured":"Cutting, G.R.: Cystic fibrosis genetics: from molecular understanding to clinical application. Nat. Rev. Genet. 16(1), 45\u201356 (2015)","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10174_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jcf.2018.05.004","volume":"18","author":"JP Clancy","year":"2019","unstructured":"Clancy, J.P., et al.: CFTR modulator theratyping: Current status, gaps and future directions. J. Cyst. Fibros. 18(1), 22\u201334 (2019)","journal-title":"J. Cyst. Fibros."},{"issue":"19","key":"10174_CR9","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","volume":"381","author":"PG Middleton","year":"2019","unstructured":"Middleton, P.G., et al.: Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N. Engl. J. Med. 381(19), 1809\u20131819 (2019)","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10174_CR10","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","volume":"379","author":"D Keating","year":"2018","unstructured":"Keating, D., et al.: VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N. Engl. J. Med. 379(17), 1612\u20131620 (2018)","journal-title":"N. Engl. J. Med."},{"issue":"2S","key":"10174_CR11","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1016\/j.jcf.2017.09.005","volume":"17","author":"DM Cholon","year":"2018","unstructured":"Cholon, D.M., Gentzsch, M.: Recent progress in translational cystic fibrosis research using precision medicine strategies. J. Cyst. Fibros. 17(2S), S52\u2013S60 (2018)","journal-title":"J. Cyst. Fibros."},{"issue":"6","key":"10174_CR12","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1085\/jgp.201812143","volume":"151","author":"A Abu-Arish","year":"2019","unstructured":"Abu-Arish, A., et al.: Agonists that stimulate secretion promote the recruitment of CFTR into membrane lipid microdomains. J. Gen. Physiol. 151(6), 834\u2013849 (2019)","journal-title":"J. Gen. Physiol."},{"issue":"6633","key":"10174_CR13","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/42408","volume":"387","author":"K Simons","year":"1997","unstructured":"Simons, K., Ikonen, E.: Functional rafts in cell membranes. Nature 387(6633), 569\u2013572 (1997)","journal-title":"Nature"},{"issue":"1","key":"10174_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.bpj.2015.04.042","volume":"109","author":"A Abu-Arish","year":"2015","unstructured":"Abu-Arish, A., et al.: Cholesterol modulates CFTR confinement in the plasma membrane of primary epithelial cells. Biophys. J. 109(1), 85\u201394 (2015)","journal-title":"Biophys. J."},{"issue":"1","key":"10174_CR15","doi-asserted-by":"publisher","first-page":"418","DOI":"10.4049\/jimmunol.172.1.418","volume":"172","author":"MP Kowalski","year":"2004","unstructured":"Kowalski, M.P., Pier, G.B.: Localization of cystic fibrosis transmembrane conductance regulator to lipid rafts of epithelial cells is required for Pseudomonas aeruginosa-induced cellular activation. J. Immunol. 172(1), 418\u2013425 (2004)","journal-title":"J. Immunol."},{"issue":"12","key":"10174_CR16","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.3390\/ijms21124486","volume":"21","author":"G Mancini","year":"2020","unstructured":"Mancini, G., et al.: GM1 as Adjuvant of Innovative Therapies for Cystic Fibrosis Disease. Int J Mol Sci 21(12), 4486 (2020)","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10174_CR17","doi-asserted-by":"publisher","first-page":"jcs259002","DOI":"10.1242\/jcs.259002","volume":"135","author":"A Abu-Arish","year":"2022","unstructured":"Abu-Arish, A., et al.: Lipid-driven CFTR clustering is impaired in cystic fibrosis and restored by corrector drugs. J Cell Sci 135(5), jcs259002 (2022)","journal-title":"J Cell Sci"},{"issue":"1","key":"10174_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s42003-020-0909-1","volume":"3","author":"KA Cottrill","year":"2020","unstructured":"Cottrill, K.A., Farinha, C.M., McCarty, N.A.: The bidirectional relationship between CFTR and lipids. Commun Biol 3(1), 179 (2020)","journal-title":"Commun Biol"},{"issue":"3","key":"10174_CR19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.bbamcr.2005.09.001","volume":"1746","author":"CR Bollinger","year":"2005","unstructured":"Bollinger, C.R., Teichgraber, V., Gulbins, E.: Ceramide-enriched membrane domains. Biochim. Biophys. Acta 1746(3), 284\u2013294 (2005)","journal-title":"Biochim. Biophys. Acta"},{"issue":"9","key":"10174_CR20","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1002\/2211-5463.13660","volume":"13","author":"D Dobi","year":"2023","unstructured":"Dobi, D., et al.: Cross-talk between CFTR and sphingolipids in cystic fibrosis. FEBS Open Bio 13(9), 1601\u20131614 (2023)","journal-title":"FEBS Open Bio"},{"issue":"6","key":"10174_CR21","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1194\/jlr.M800427-JLR200","volume":"50","author":"H Hamai","year":"2009","unstructured":"Hamai, H., et al.: Defective CFTR increases synthesis and mass of sphingolipids that modulate membrane composition and lipid signaling. J. Lipid Res. 50(6), 1101\u20131108 (2009)","journal-title":"J. Lipid Res."},{"key":"10174_CR22","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.plipres.2019.03.001","volume":"74","author":"D Garic","year":"2019","unstructured":"Garic, D., et al.: Biochemistry of very-long-chain and long-chain ceramides in cystic fibrosis and other diseases: The importance of side chain. Prog. Lipid Res. 74, 130\u2013144 (2019)","journal-title":"Prog. Lipid Res."},{"issue":"9","key":"10174_CR23","doi-asserted-by":"publisher","first-page":"C819","DOI":"10.1152\/ajpcell.00168.2013","volume":"306","author":"Y Itokazu","year":"2014","unstructured":"Itokazu, Y., et al.: Reduced GM1 ganglioside in CFTR-deficient human airway cells results in decreased beta1-integrin signaling and delayed wound repair. Am. J. Physiol. Cell Physiol. 306(9), C819\u2013C830 (2014)","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"4","key":"10174_CR24","doi-asserted-by":"publisher","first-page":"C872","DOI":"10.1152\/ajpcell.00507.2010","volume":"301","author":"E Sondo","year":"2011","unstructured":"Sondo, E., et al.: Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling. Am. J. Physiol. Cell Physiol. 301(4), C872\u2013C885 (2011)","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10174_CR25","doi-asserted-by":"crossref","unstructured":"Veit, G., et al., Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination. JCI Insight. 5(18), e139983 (2020)","DOI":"10.1172\/jci.insight.139983"},{"issue":"3","key":"10174_CR26","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/j.1471-4159.2005.03397.x","volume":"95","author":"N Loberto","year":"2005","unstructured":"Loberto, N., et al.: The membrane environment of endogenous cellular prion protein in primary rat cerebellar neurons. J. Neurochem. 95(3), 771\u2013783 (2005)","journal-title":"J. Neurochem."},{"issue":"2","key":"10174_CR27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1471-4159.2008.05591.x","volume":"107","author":"F Scandroglio","year":"2008","unstructured":"Scandroglio, F., et al.: Lipid content of brain, brain membrane lipid domains, and neurons from acid sphingomyelinase deficient mice. J. Neurochem. 107(2), 329\u2013338 (2008)","journal-title":"J. Neurochem."},{"issue":"5","key":"10174_CR28","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s10719-020-09935-x","volume":"37","author":"N Loberto","year":"2020","unstructured":"Loberto, N., et al.: Sphingolipids and plasma membrane hydrolases in human primary bronchial cells during differentiation and their altered patterns in cystic fibrosis. Glycoconj. J. 37(5), 623\u2013633 (2020)","journal-title":"Glycoconj. J."},{"key":"10174_CR29","doi-asserted-by":"publisher","first-page":"1730245","DOI":"10.1155\/2017\/1730245","volume":"2017","author":"D Schiumarini","year":"2017","unstructured":"Schiumarini, D., et al.: Evidence for the Involvement of Lipid Rafts and Plasma Membrane Sphingolipid Hydrolases in Pseudomonas aeruginosa Infection of Cystic Fibrosis Bronchial Epithelial Cells. Mediators Inflamm. 2017, 1730245 (2017)","journal-title":"Mediators Inflamm."},{"issue":"8","key":"10174_CR30","doi-asserted-by":"publisher","first-page":"5574","DOI":"10.1074\/jbc.M207269200","volume":"278","author":"A Prinetti","year":"2003","unstructured":"Prinetti, A., et al.: Altered sphingolipid metabolism in N-(4-hydroxyphenyl)-retinamide-resistant A2780 human ovarian carcinoma cells. J. Biol. Chem. 278(8), 5574\u20135583 (2003)","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10174_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/0003-2697(86)90094-1","volume":"153","author":"V Chigorno","year":"1986","unstructured":"Chigorno, V., et al.: A radiometric assay for ganglioside sialidase applied to the determination of the enzyme subcellular location in cultured human fibroblasts. Anal. Biochem. 153(2), 283\u2013294 (1986)","journal-title":"Anal. Biochem."},{"key":"10174_CR32","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.chemphyslip.2016.08.002","volume":"200","author":"M Aureli","year":"2016","unstructured":"Aureli, M., et al.: Unravelling the role of sphingolipids in cystic fibrosis lung disease. Chem. Phys. Lipids 200, 94\u2013103 (2016)","journal-title":"Chem. Phys. Lipids"},{"issue":"5","key":"10174_CR33","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1111\/j.1471-4159.2010.07019.x","volume":"116","author":"M Aureli","year":"2011","unstructured":"Aureli, M., et al.: Cell surface sphingolipid glycohydrolases in neuronal differentiation and aging in culture. J. Neurochem. 116(5), 891\u2013899 (2011)","journal-title":"J. Neurochem."},{"key":"10174_CR34","doi-asserted-by":"crossref","unstructured":"Becq, F., et al., The rescue of F508del-CFTR by elexacaftor\/tezacaftor\/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor. Eur Respir J, 2022. 59(2).","DOI":"10.1183\/13993003.00671-2021"},{"key":"10174_CR35","doi-asserted-by":"publisher","first-page":"1114584","DOI":"10.3389\/fphar.2023.1114584","volume":"14","author":"F Stanke","year":"2023","unstructured":"Stanke, F., et al.: Changes in cystic fibrosis transmembrane conductance regulator protein expression prior to and during elexacaftor-tezacaftor-ivacaftor therapy. Front. Pharmacol. 14, 1114584 (2023)","journal-title":"Front. Pharmacol."},{"issue":"6","key":"10174_CR36","doi-asserted-by":"publisher","first-page":"20002774","DOI":"10.1183\/13993003.02774-2020","volume":"57","author":"O Laselva","year":"2021","unstructured":"Laselva, O., et al.: Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator. Eur Respir J 57(6), 20002774 (2021)","journal-title":"Eur Respir J"},{"issue":"6","key":"10174_CR37","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1091\/mbc.e04-03-0176","volume":"15","author":"M Gentzsch","year":"2004","unstructured":"Gentzsch, M., et al.: Endocytic trafficking routes of wild type and DeltaF508 cystic fibrosis transmembrane conductance regulator. Mol. Biol. Cell 15(6), 2684\u20132696 (2004)","journal-title":"Mol. Biol. Cell"},{"issue":"2S","key":"10174_CR38","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.jcf.2017.08.014","volume":"17","author":"CM Farinha","year":"2018","unstructured":"Farinha, C.M., Miller, E., McCarty, N.: Protein and lipid interactions - Modulating CFTR trafficking and rescue. J. Cyst. Fibros. 17(2S), S9\u2013S13 (2018)","journal-title":"J. Cyst. Fibros."},{"issue":"6","key":"10174_CR39","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1021\/cr0100446","volume":"106","author":"S Sonnino","year":"2006","unstructured":"Sonnino, S., et al.: Dynamic and structural properties of sphingolipids as driving forces for the formation of membrane domains. Chem. Rev. 106(6), 2111\u20132125 (2006)","journal-title":"Chem. Rev."},{"key":"10174_CR40","doi-asserted-by":"crossref","unstructured":"Liessi, N., et al., Distinctive lipid signatures of bronchial epithelial cells associated with cystic fibrosis drugs, including Trikafta. JCI Insight. 5(16), e138722 (2020)","DOI":"10.1172\/jci.insight.138722"},{"issue":"6\u20137","key":"10174_CR41","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1515\/hsz-2014-0285","volume":"396","author":"AP Seitz","year":"2015","unstructured":"Seitz, A.P., et al.: Ceramide and sphingosine in pulmonary infections. Biol. Chem. 396(6\u20137), 611\u2013620 (2015)","journal-title":"Biol. Chem."},{"issue":"4","key":"10174_CR42","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/nm1748","volume":"14","author":"V Teichgraber","year":"2008","unstructured":"Teichgraber, V., et al.: Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis. Nat. Med. 14(4), 382\u2013391 (2008)","journal-title":"Nat. Med."},{"key":"10174_CR43","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.addr.2018.04.015","volume":"133","author":"KA Becker","year":"2018","unstructured":"Becker, K.A., et al.: Sphingolipids as targets for inhalation treatment of cystic fibrosis. Adv. Drug Deliv. Rev. 133, 66\u201375 (2018)","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["Glycoconjugate Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10719-024-10174-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10719-024-10174-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10719-024-10174-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T04:36:10Z","timestamp":1739939770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10719-024-10174-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,11]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10174"],"URL":"https:\/\/doi.org\/10.1007\/s10719-024-10174-7","relation":{},"ISSN":["0282-0080","1573-4986"],"issn-type":[{"value":"0282-0080","type":"print"},{"value":"1573-4986","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,11]]},"assertion":[{"value":"14 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}